Back

Efficacy and safety of inclisiran monotherapy in patients with hypercholesterolemia without background lipid-lowering therapy: a systematic review and meta-analysis

24 April 2026 (11:00 - 11:45)
Organised by: Logo
Congress Presentation Part of: Achieving lipid goals in the real world (1) Drug therapy EAPC Premium Access ESC Preventive Cardiology 2026 European Association of Preventive Cardiology (EAPC)

About the speaker

Photo
Associate Professor Edin Begic

General hospital Prim Dr Abdulah Nakas, Sarajevo (Bosnia and Herzegovina)

5 More presentations in this session

Presentation thumbnail
Urate dynamics, gout events, and tolerability of bempedoic acid for primary ASCVD prevention: a real-world retrospective review from rural primary care in England
Mrs M. Donaldson (Louth, GB)
Abstract Slides
Presentation thumbnail
Impact of revised 2025 ESC/EAS guidelines for the management of dyslipidaemias in the community
Doctor N. Ahanchi (Fribourg, CH)
Abstract Slides
Presentation thumbnail
Nurse-led secondary prevention lipid clinic
Mr A. Young (Bournemouth, GB)
Abstract Slides
Presentation thumbnail
Reclassifying high-risk primary prevention: real-world LDL-C reduction with bempedoic acid in a multimorbid rural population
Doctor C. Deaney (Louth, GB)
Abstract Slides
Presentation thumbnail
Low density lipoprotein-Cholesterol levels evaluation in the total population and subgroup of non-diabetic dyslipidemic Greek patients of ZEUS study under fixed-dose-combination ezetimibe/rosuvastatin
Mr G. Tsioumas (Athens, GR)
Abstract Slides

Access the full session

Session thumbnail
Achieving lipid goals in the real world (1)

The Event

Event poster

ESC Preventive Cardiology 2026

24 April 2026 11:00 CET
You may be interested in
thumbnail
Congress Presentation
Efficacy of inclisiran versus placebo in atherosclerotic cardiovascular disease: A systematic review and meta-analysis
thumbnail
Congress Presentation
Efficacy and safety of inclisiran in reducing LDL cholesterol and triglycerides: real-life experience in a third level hospital: a descriptive, bivariate, and multivariate analysis.
thumbnail
Congress Presentation
VICTORION-Mono China: efficacy and safety of inclisiran as monotherapy in Chinese adults with low or moderate ASCVD risk and elevated LDL-C

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources